Trial of Spesolimab for Generalized Pustular Psoriasis

Trial of Spesolimab for Generalized Pustular Psoriasis

In a randomized trial involving patients with the rare but disabling disorder generalized pustular psoriasis, the anti–interleukin-36 monoclonal antibody spesolimab greatly curtailed disease activity as compared with placebo over a period of 1 week. Systemic drug reactions and infections occurred wi...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The New England journal of medicine 2021-12, Vol.385 (26), p.2431-2440
Hauptverfasser: Bachelez, Hervé, Choon, Siew-Eng, Marrakchi, Slaheddine, Burden, A. David, Tsai, Tsen-Fang, Morita, Akimichi, Navarini, Alexander A, Zheng, Min, Xu, Jinhua, Turki, Hamida, Anadkat, Milan J, Rajeswari, Sushmita, Hua, Hairui, Vulcu, Sebastian D, Hall, David, Tetzlaff, Kay, Thoma, Christian, Lebwohl, Mark G
Format: Artikel
Sprache:eng
Schlagworte:
Adult
Aged
Allergy
Antibodies, Monoclonal, Humanized - administration & dosage
Antibodies, Monoclonal, Humanized - adverse effects
Antibodies, Monoclonal, Humanized - therapeutic use
Autoimmune Disease
Autoimmune diseases
Clinical medicine
Clinical trials
Cytokines
Dermatology
Double-Blind Method
Drug dosages
Erythema
Female
Humans
Immunology
Injections, Intravenous
Intravenous administration
Male
Middle Aged
Monoclonal antibodies
Mutation
Pain
Patient safety
Patients
Placebos
Placebos - adverse effects
Placebos - therapeutic use
Psoriasis
Psoriasis - drug therapy
Receptors, Interleukin - antagonists & inhibitors
Severity of Illness Index
Skin
Skin diseases
Statistical analysis
Symptom Flare Up
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:In a randomized trial involving patients with the rare but disabling disorder generalized pustular psoriasis, the anti–interleukin-36 monoclonal antibody spesolimab greatly curtailed disease activity as compared with placebo over a period of 1 week. Systemic drug reactions and infections occurred with spesolimab.
ISSN:0028-4793
1533-4406
DOI:10.1056/NEJMoa2111563